The 12-16-week open-label study evaluated Ruxoprubart as monotherapy in treatment-naïve PNH patients. Key findings include: CLEVELAND, March 09, 2026 (GLOBE NEWSWIRE) -- NovelMed Therapeutics Inc., a ...
New training materials for maintenance technicians include 3D models and video instruction. LONDON, UNITED KINGDOM, ...
When an AI system in health care gives a confident answer, should clinicians trust it? In a new article from Frontiers in ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果